We bring you the latest news from the healthcare about the health care in the United Kingdom. Do your have news for us? Contact the editor. Watch also this special movie.

donderdag 20 juli 2017

The Lancet: [Comment] PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer

[Comment] PD-1 inhibition in metastatic dMMR/MSI-H colorectal cancer
Restoring the host immune response against cancer cells through blockade of the PD-1 axis is an established treatment strategy for several tumour types. Findings of initial studies of PD-1 inhibitors in metastatic colorectal cancer were not especially promising. Nonetheless, they suggested the existence of a subset of patients who might benefit substantially from immunotherapy. These patients were identified as having DNA mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) tumours, which are characterised by a high mutational load, high numbers of antigenic neo-epitopes, abundant infiltration of CD8+ cytotoxic lymphocytes, and upregulation of immune checkpoints.
Read more

[Articles] Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Nivolumab provided durable responses and disease control in pre-treated patients with dMMR/MSI-H metastatic colorectal cancer, and could be a new treatment option for these patients.
Read more

[Articles] Asparaginase-associated pancreatitis in childhood acute lymphoblastic leukaemia: an observational Ponte di Legno Toxicity Working Group study
Since the risk of a second asparaginase-associated pancreatitis was not associated with severity of the first asparaginase-associated pancreatitis and a second asparaginase-associated pancreatitis did not involve an increased risk of complications, asparaginase re-exposure should be determined mainly by the anticipated need for asparaginase for antileukaemic efficacy. A study of the genetic risk factors identifying patients in whom asparaginase exposure should be restricted is needed.
Read more

[News] Protein biomarker for pancreatic ductal adenocarcinoma
Researchers in the USA have created a biomarker panel that can detect early-stage and late-stage pancreatic cancer. In earlier work, with a cell model that mimics the progression of pancreatic ductal adenocarcinoma, the investigators identified 107 proteins that are secreted and released by early-stage disease. In this study, they found that one such protein, thrombospondin-2 (THBS2), could distinguish all stages of the disease from healthy tissue.
Read more

[News] Surgery no better than observation for localised prostate cancer
New research suggests that in patients with localised prostate cancer, prostatectomy does not significantly reduce all-cause mortality or prostate cancer mortality, when compared with observation, over a 20-year follow-up.
Read more